comprehensive -WSS

comprehensive

author：focus 2025-10-02 22:25:10 - browse：443

ESMO signage in Madrid. — At ESMO 2023, antibody-drug conjugates were featured prominently. Andrew Joseph/STAT

MADRID — If you had to pinpoint one subject that stood out at this year’s European Society for Medical Oncology meeting, a massive conference with thousands of people from 140-some countries and 2,500 studies presented, it would be a burgeoning type of cancer treatment called antibody-drug conjugates.

The conference opened to the news that Merck had signed one of the biggest licensing deals in industry history — worth up to $22 billion — to partner on three of the compounds from ADC specialist Daiichi Sankyo. GSK followed up with an ADC licensing announcement of its own (if a much smaller one). Multiple ADC studies were presented at the meeting’s top sessions. ADCs were, in short, the belle of the cancer research ball.

The thing is, ADCs are actually quite an old approach.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Cholera vaccine supplies dangerously low, outbreaks surging

WSS

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

First Opinion Podcast: What happens when kids become caregivers?

Focused ultrasound for uterine fibroids: an uphill battle

Report: NIH

Childbirth

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

focus

comprehensive

Wikipedia

ChatGPT in medicine: STAT answers readers' burning questions

CDC advisory group OKs chikungunya vaccine

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare Advantage isn’t working — for anyone

Medicare details structure of new drug price negotiation program

Focused ultrasound for uterine fibroids: an uphill battle

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

'Vaccine

Medical leaders decry Supreme Court decision on affirmative action

Focused ultrasound for uterine fibroids: an uphill battle

entertainment

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Pfizer is about to make a big push in cancer. Will investors listen?

Medicare Advantage isn’t working — for anyone

Dark money group runs ads on China biotech bill

Startling documents reveal new facets of Sacklers' opioid empire

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

focus

entertainment

hotspot

focus